-
Je něco špatně v tomto záznamu ?
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial
SA. Murphy, TR. Pedersen, ZA. Gaciong, R. Ceska, MV. Ezhov, DL. Connolly, JW. Jukema, K. Toth, MJ. Tikkanen, K. Im, SD. Wiviott, CE. Kurtz, N. Honarpour, RP. Giugliano, AC. Keech, PS. Sever, MS. Sabatine,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
- MeSH
- anticholesteremika aplikace a dávkování MeSH
- cévní mozková příhoda prevence a kontrola MeSH
- dvojitá slepá metoda MeSH
- humanizované monoklonální protilátky aplikace a dávkování MeSH
- infarkt myokardu prevence a kontrola MeSH
- injekce subkutánní MeSH
- kardiovaskulární nemoci farmakoterapie MeSH
- koronární angioplastika statistika a číselné údaje MeSH
- lidé středního věku MeSH
- lidé MeSH
- následné studie MeSH
- nestabilní angina pectoris prevence a kontrola MeSH
- PCSK9 inhibitory MeSH
- proproteinkonvertasa subtilisin/kexin typu 9 MeSH
- rozvrh dávkování léků MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- srovnávací studie MeSH
Importance: The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol and first cardiovascular events in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial, but patients remain at high risk of recurrent cardiovascular events. Objective: To evaluate the effect of evolocumab on total cardiovascular events, given the importance of total number of cardiovascular events to patients, clinicians, and health economists. Design, Setting, and Participants: Secondary analysis of a randomized, double-blind clinical trial. The FOURIER trial compared evolocumab or matching placebo and followed up patients for a median of 2.2 years. The study included 27 564 patients with stable atherosclerotic disease receiving statin therapy. Data were analyzed between May 2017 and February 2019. Main Outcomes and Measures: The primary end point (PEP) was time to first cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization; the key secondary end point was time to first cardiovascular death, myocardial infarction, or stroke. In a prespecified analysis, total cardiovascular events were evaluated between treatment arms. Results: The mean age of patients was 63 years, 69% of patients were taking high-intensity statin therapy, and the median LDL-C at baseline was 92 mg/dL (to convert to millimoles per liter, multiply by 0.0259). There were 2907 first PEP events and 4906 total PEP events during the trial. Evolocumab reduced total PEP events by 18% (incidence rate ratio [RR], 0.82; 95% CI, 0.75-0.90; P < .001) including both first events (hazard ratio, 0.85; 95% CI, 0.79-0.92; P < .001) and subsequent events (RR, 0.74; 95% CI, 0.65-0.85). There were 2192 total primary events in the evolocumab group and 2714 total events in the placebo group. For every 1000 patients treated for 3 years, evolocumab prevented 22 first PEP events and 52 total PEP events. Reductions in total events were driven by fewer total myocardial infarctions (RR, 0.74; 95% CI, 0.65-0.84; P < .001), strokes (RR, 0.77; 95% CI, 0.64-0.93; P = .007), and coronary revascularizations (RR, 0.78; 95% CI, 0.71-0.87; P < .001). Conclusions and Relevance: The addition of the PCSK9 inhibitor evolocumab to statin therapy improved clinical outcomes, with significant reductions in total PEP events, driven by decreases in myocardial infarction, stroke, and coronary revascularization. More than double the number of events were prevented with evolocumab vs placebo as compared with the analysis of only first events. These data provide further support for the benefit of continuing aggressive lipid-lowering therapy to prevent recurrent cardiovascular events. Trial Registration: ClinicalTrials.gov identifier: NCT01764633.
1st Department of Medicine University of Pecs Medical School Pecs Hungary
Amgen Thousand Oaks California
Department of Cardiology Leiden University Medical Center Leiden the Netherlands
Folkhälsan Research Center University of Helsinki Helsinki Finland
Imperial College London London England
National Cardiology Research Center Moscow Russia
Oslo University Hospital Ullevål and Medical Faculty University of Oslo Oslo Norway
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023856
- 003
- CZ-PrNML
- 005
- 20201214131441.0
- 007
- ta
- 008
- 201125s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1001/jamacardio.2019.0886 $2 doi
- 035 __
- $a (PubMed)31116355
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Murphy, Sabina A $u TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Masschusetts.
- 245 10
- $a Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial / $c SA. Murphy, TR. Pedersen, ZA. Gaciong, R. Ceska, MV. Ezhov, DL. Connolly, JW. Jukema, K. Toth, MJ. Tikkanen, K. Im, SD. Wiviott, CE. Kurtz, N. Honarpour, RP. Giugliano, AC. Keech, PS. Sever, MS. Sabatine,
- 520 9_
- $a Importance: The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol and first cardiovascular events in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial, but patients remain at high risk of recurrent cardiovascular events. Objective: To evaluate the effect of evolocumab on total cardiovascular events, given the importance of total number of cardiovascular events to patients, clinicians, and health economists. Design, Setting, and Participants: Secondary analysis of a randomized, double-blind clinical trial. The FOURIER trial compared evolocumab or matching placebo and followed up patients for a median of 2.2 years. The study included 27 564 patients with stable atherosclerotic disease receiving statin therapy. Data were analyzed between May 2017 and February 2019. Main Outcomes and Measures: The primary end point (PEP) was time to first cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization; the key secondary end point was time to first cardiovascular death, myocardial infarction, or stroke. In a prespecified analysis, total cardiovascular events were evaluated between treatment arms. Results: The mean age of patients was 63 years, 69% of patients were taking high-intensity statin therapy, and the median LDL-C at baseline was 92 mg/dL (to convert to millimoles per liter, multiply by 0.0259). There were 2907 first PEP events and 4906 total PEP events during the trial. Evolocumab reduced total PEP events by 18% (incidence rate ratio [RR], 0.82; 95% CI, 0.75-0.90; P < .001) including both first events (hazard ratio, 0.85; 95% CI, 0.79-0.92; P < .001) and subsequent events (RR, 0.74; 95% CI, 0.65-0.85). There were 2192 total primary events in the evolocumab group and 2714 total events in the placebo group. For every 1000 patients treated for 3 years, evolocumab prevented 22 first PEP events and 52 total PEP events. Reductions in total events were driven by fewer total myocardial infarctions (RR, 0.74; 95% CI, 0.65-0.84; P < .001), strokes (RR, 0.77; 95% CI, 0.64-0.93; P = .007), and coronary revascularizations (RR, 0.78; 95% CI, 0.71-0.87; P < .001). Conclusions and Relevance: The addition of the PCSK9 inhibitor evolocumab to statin therapy improved clinical outcomes, with significant reductions in total PEP events, driven by decreases in myocardial infarction, stroke, and coronary revascularization. More than double the number of events were prevented with evolocumab vs placebo as compared with the analysis of only first events. These data provide further support for the benefit of continuing aggressive lipid-lowering therapy to prevent recurrent cardiovascular events. Trial Registration: ClinicalTrials.gov identifier: NCT01764633.
- 650 _2
- $a nestabilní angina pectoris $x prevence a kontrola $7 D000789
- 650 _2
- $a humanizované monoklonální protilátky $x aplikace a dávkování $7 D061067
- 650 _2
- $a anticholesteremika $x aplikace a dávkování $7 D000924
- 650 _2
- $a kardiovaskulární nemoci $x farmakoterapie $7 D002318
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a rozvrh dávkování léků $7 D004334
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a injekce subkutánní $7 D007279
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a infarkt myokardu $x prevence a kontrola $7 D009203
- 650 _2
- $a koronární angioplastika $x statistika a číselné údaje $7 D062645
- 650 _2
- $a proproteinkonvertasa subtilisin/kexin typu 9 $7 D000071449
- 650 _2
- $a cévní mozková příhoda $x prevence a kontrola $7 D020521
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a PCSK9 inhibitory $7 D000091362
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pedersen, Terje R $u Oslo University Hospital, Ullevål and Medical Faculty, University of Oslo, Oslo, Norway.
- 700 1_
- $a Gaciong, Zbigniew A $u Department of Internal Medicine, Hypertension and Vascular Diseases, The Medical University of Warsaw, Warsaw, Poland.
- 700 1_
- $a Ceska, Richard $u Center for Preventive Cardiology, 3rd Internal Medicine Clinic, University General Hospital and Charles University 1st Medical Faculty, Prague, Czech Republic.
- 700 1_
- $a Ezhov, Marat V $u National Cardiology Research Center, Moscow, Russia.
- 700 1_
- $a Connolly, Derek L $u Birmingham City and Sandwell Hospitals and the Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, England.
- 700 1_
- $a Jukema, J Wouter $u Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.
- 700 1_
- $a Toth, Kalman $u First Department of Medicine, University of Pecs, Medical School, Pecs, Hungary.
- 700 1_
- $a Tikkanen, Matti J $u Folkhälsan Research Center, University of Helsinki, Helsinki, Finland.
- 700 1_
- $a Im, Kyungah $u TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Masschusetts.
- 700 1_
- $a Wiviott, Stephen D $u TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Masschusetts.
- 700 1_
- $a Kurtz, Christopher E $u Amgen, Thousand Oaks, California.
- 700 1_
- $a Honarpour, Narimon $u Amgen, Thousand Oaks, California.
- 700 1_
- $a Giugliano, Robert P $u TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Masschusetts.
- 700 1_
- $a Keech, Anthony C $u Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia.
- 700 1_
- $a Sever, Peter S $u Imperial College London, London, England.
- 700 1_
- $a Sabatine, Marc S $u TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Masschusetts. Deputy Editor.
- 773 0_
- $w MED00191356 $t JAMA cardiology $x 2380-6591 $g Roč. 4, č. 7 (2019), s. 613-619
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31116355 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214131439 $b ABA008
- 999 __
- $a ok $b bmc $g 1596175 $s 1114532
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 4 $c 7 $d 613-619 $e 20190701 $i 2380-6591 $m JAMA cardiology $n JAMA Cardiol $x MED00191356
- LZP __
- $a Pubmed-20201125